Copanlisib monotherapy has demonstrated durable and rapid objective responses in patients with heavily pre-treated indolent lymphoma, with a manageable safety profile, and is approved for the treatment of patients with relapsed follicular lymphoma.

The intravenous route of administration and intermittent dosing schedule of copanlisib may support a favorable tolerability profile over continuously administered oral alternatives.

Ongoing studies are evaluating the safety and efficacy of copanlisib in combination with rituximab and standard-of-care chemotherapy in patients with relapsed indolent lymphoma and may support the use of copanlisib in the second-line setting as part of a combination regimen if the results are positive.